Stephen Ranere is a partner in the Boston office of Latham & Watkins and a member of the firm's Emerging Companies & Growth Practice. He represents both public and private companies, along with venture capital firms involved in the technology and life sciences industries.

Mr. Ranere’s practice focuses on a broad range of legal representation, including general corporate counseling, early stage company formation and strategy, initial through late stage venture capital financings, mergers and acquisitions, public securities offerings, and public company representation.

Mr. Ranere was a member of the Suffolk University Law Review and was awarded the Daniel J. Fern Award for highest grade point average.

Prior to law school, Mr. Ranere held business development positions with Sophos, a provider of network anti-virus solutions, and CipherTrust (later acquired by McAfee), a provider of email and internet security products.

Mr. Ranere’s representative transactions include:


  • MadHive on its US$300 million investment from Goldman Sachs Asset Management
  • Merlin Labs on its US$105 million Series B financing
  • OfferFit on its numerous debt and equity financings 
  • Robin on its US$30 million Series C financing
  • Owkin on its US$180 million investment from Sanofi, US$80 million investment from BMS and other equity financings
  • Overjet on its numerous debt and equity financings
  • Riversand Technologies on its sale to Syndigo
  • Evolv Technology on its US$1.7 billion SPAC merger with NewHold Investment Corporation
  • PathAI on its US$165 million Series C financing
  • Actifio on its sale to Google and numerous debt and equity financings
  • Charles River Systems on its US$2.6 billion sale to State Street Corporation
  • Amphenol on its US$400 million acquisition of SSI Controls Technologies
  • Veracode on its US$614 million sale to CA Technologies
  • CloudHealth on its sale to VMware, Inc.
  • in its IPO and numerous acquisitions
  • Zipcar on its IPO and sale to Avis Budget Group

Life Sciences

  • Affini-T Therapeutics on its US$175 million equity financing
  • BlueWhale Bio on its US$18 million seed financing 
  • Rapid Micro Biosystems on its IPO and multiple private financings and strategic transactions
  • Neurogene on its US$115 million equity financing and numerous other private financings
  • Kiniksa Pharmaceuticals on its US$150 million IPO and multiple private financings and strategic transactions

Bar Qualification

  • Massachusetts


  • JD, Suffolk University Law School, 2008
    summa cum laude
  • BA, Harvard University, 2000